Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2026
Characterization of Cognitive-Behavioral Counseling Duration Thresholds for Effective Tobacco Treatment.
Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThe purpose of this study was to characterize the dose-response relationship between duration of cognitive-behavioral counseling and abstinence in individuals who participated in a randomized controlled trial for smoking cessation.
methodsThis is a secondary analysis of participants enrolled in double-blind randomized controlled trials for smoking cessation consisting of 12 weeks of pharmacotherapy (placebo; N = 142; varenicline; N = 257) combined with counseling. Participants were 41% female, 66% non-Hispanic White, who smoked a median of 20 cigarettes per day. Seven-day point prevalence (7-dayPP) and prolonged abstinence were calculated at the end of treatment and at the 6-month follow-up.
resultsAll abstinence outcomes exhibited sigmoidal (s-shaped) relationships with duration of counseling, and the median effective duration was similar (ranging from 130 to 160 min). The sigmoidal curves between placebo and varenicline were significantly different (7-dayPP at end of treatment; EOT: F = 14.68, p < .01) The difference between the maximum efficacy for the medications is 0.34 (p-value < 0.01) for 7-dayPP abstinence at EOT, indicating ~35% higher rates of abstinence at the maximum efficacy of counseling for those in the varenicline group as compared with those in the placebo group.
conclusionsParticipants who received counseling and pharmacotherapy to quit smoking exhibited a duration-dependent response of abstinence to counseling captured by a sigmoidal curve that exhibited variation in the maximum efficacy between placebo and varenicline, suggesting either that counseling for smoking cessation enhanced the effect of varenicline on abstinence, or more likely, that counseling was more effective in achieving abstinence in the presence of varenicline. IMPLICATIONS: The results suggest that cognitive-behavioral counseling for smoking cessation is more effective in achieving abstinence in the presence of varenicline or less likely, that counseling enhanced the effect of varenicline on abstinence. Optimizing the duration of counseling, particularly when coupled with pharmacotherapy, can offer more tailored and efficient cessation strategies. This finding emphasizes that the integration of behavioral and pharmacological approaches is crucial for maximizing the effectiveness of smoking cessation interventions, consistent with previous evidence and current guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.